{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:06:57Z","timestamp":1763762817632,"version":"3.45.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cld.2025.08.006","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:39:51Z","timestamp":1760139591000},"page":"55-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medical Treatments and Outcomes in Acute Alcohol-Related Hepatitis"],"prefix":"10.1016","volume":"30","author":[{"given":"Howard D.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian P.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cld.2025.08.006_bib1","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/HEP.0000000000000899","article-title":"Alcohol-associated liver disease-global epidemiology","volume":"80","author":"\u00c5berg","year":"2024","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2025.08.006_bib2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jhep.2020.11.042","article-title":"The global burden of cirrhosis: a review of disability-adjusted life-years lost and unmet needs","volume":"75","author":"Jepsen","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.08.006_bib3","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1002\/hep.32067","article-title":"Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the USA","volume":"74","author":"Cholankeril","year":"2021","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2025.08.006_bib4","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.cgh.2019.01.026","article-title":"Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide","volume":"17","author":"Shah","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jhep.2018.05.001","article-title":"Grand rounds: alcoholic hepatitis","volume":"69","author":"Singal","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2018.02.022","article-title":"The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis","volume":"69","author":"Serst\u00e9","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2021.7683","article-title":"Diagnosis and treatment of alcohol-associated liver disease: a review","volume":"326","author":"Singal","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cld.2025.08.006_bib8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American association for the study of liver diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2025.08.006_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cgh.2016.08.047","article-title":"Medical management of severe alcoholic hepatitis: expert review from the clinical practice updates committee of the AGA institute","volume":"15","author":"Mitchell","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.08.006_bib10","doi-asserted-by":"crossref","first-page":"752","DOI":"10.5604\/01.3001.0012.3132","article-title":"Adherence to appropriate nutrition in acute alcoholic hepatitis is low","volume":"17","author":"Trieu","year":"2018","journal-title":"Ann Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.08.006_bib11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.cld.2021.03.002","article-title":"Malnutrition and alcohol-associated hepatitis","volume":"25","author":"McClain","year":"2021","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2025.08.006_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cld.2018.09.005","article-title":"Acute alcoholic hepatitis","volume":"23","author":"Im","year":"2019","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0002-9343(84)90776-9","article-title":"Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans administration cooperative study group on alcoholic hepatitis","volume":"76","author":"Mendenhall","year":"1984","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.cld.2025.08.006_bib14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1530-0277.1995.tb01560.x","article-title":"Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two veterans administration cooperative studies","volume":"19","author":"Mendenhall","year":"1995","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/ajcn\/43.2.213","article-title":"VA cooperative study on alcoholic hepatitis. II: prognostic significance of protein-calorie malnutrition","volume":"43","author":"Mendenhall","year":"1986","journal-title":"Am J Clin Nutr"},{"issue":"9","key":"10.1016\/j.cld.2025.08.006_bib16","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1111\/liv.12798","article-title":"Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis","volume":"35","author":"Fialla","year":"2015","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.cld.2025.08.006_bib17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1155\/2012\/945707","article-title":"A meta-analysis of nutritional supplementation for management of hospitalized alcoholic hepatitis","volume":"26","author":"Antar","year":"2012","journal-title":"Can J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2025.08.006_bib18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1053\/j.gastro.2015.12.038","article-title":"Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids","volume":"150","author":"Moreno","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11938-017-0132-4","article-title":"Role of zinc in the development\/progression of alcoholic liver disease","volume":"15","author":"McClain","year":"2017","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2025.08.006_bib20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jhep.2005.11.039","article-title":"Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial","volume":"44","author":"Phillips","year":"2006","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.08.006_bib21","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.29240","article-title":"Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study","volume":"66","author":"Louvet","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2025.08.006_bib22","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep.29338","article-title":"Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long-term survival","volume":"66","author":"Altamirano","year":"2017","journal-title":"Hepatology"},{"issue":"26","key":"10.1016\/j.cld.2025.08.006_bib23","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMra2207599","article-title":"Alcohol-associated hepatitis","volume":"387","author":"Bataller","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.cld.2025.08.006_bib24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: a review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2796.1992.tb00562.x","article-title":"Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish committee on adverse drug reactions between 1978 and 1987","volume":"232","author":"Friis","year":"1992","journal-title":"J Intern Med"},{"issue":"5","key":"10.1016\/j.cld.2025.08.006_bib26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00002018-199920050-00003","article-title":"Safety issues concerning the use of disulfiram in treating alcohol dependence","volume":"20","author":"Chick","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.cld.2025.08.006_bib27","first-page":"59","article-title":"Disulfiram therapy--adverse drug reactions and interactions","volume":"369","author":"Enghusen","year":"1992","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"9","key":"10.1016\/j.cld.2025.08.006_bib28","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.mayocp.2020.01.030","article-title":"Evidence-based pharmacotherapies for alcohol use disorder: clinical pearls","volume":"95","author":"Fairbanks","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcp.12070","article-title":"The clinical pharmacology of acamprosate","volume":"77","author":"Kalk","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cld.2025.08.006_bib30","article-title":"ReVia (naltrexone) package insert","volume":"DE","author":"ReVia","year":"2006","journal-title":"DuPont (US) Wilmington"},{"issue":"12","key":"10.1016\/j.cld.2025.08.006_bib31","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archpsyc.1997.01830240090013","article-title":"The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The naltrexone usage study group","volume":"54","author":"Croop","year":"1997","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"10.1016\/j.cld.2025.08.006_bib32","article-title":"Safety of naltrexone in patients with cirrhosis","volume":"6","author":"Thompson","year":"2024","journal-title":"JHEP Rep"},{"issue":"9603","key":"10.1016\/j.cld.2025.08.006_bib33","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cld.2025.08.006_bib34","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2018.03.017","article-title":"Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis","volume":"28","author":"Pierce","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.cld.2025.08.006_bib35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/alcalc\/agx030","article-title":"A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-the ALPADIR study","volume":"52","author":"Reynaud","year":"2017","journal-title":"Alcohol Alcohol"},{"issue":"7","key":"10.1016\/j.cld.2025.08.006_bib36","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/add.13787","article-title":"The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial","volume":"112","author":"Hauser","year":"2017","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.cld.2025.08.006_bib37","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1053\/j.gastro.2021.08.004","article-title":"Results of early transplantation for alcohol-related cirrhosis: integrated addiction treatment with low rate of relapse","volume":"161","author":"Carrique","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cgh.2019.04.048","article-title":"Alcohol rehabilitation within 30 days of hospital discharge is associated with reduced readmission, relapse, and death in patients with alcoholic hepatitis","volume":"18","author":"Peeraphatdit","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","article-title":"Corticosteroid therapy of alcoholic hepatitis","volume":"75","author":"Maddrey","year":"1978","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.14309\/ajg.0000000000001596","article-title":"The MELD score is superior to the maddrey discriminant function score to predict short-term mortality in alcohol-associated hepatitis: a global study","volume":"117","author":"Morales-Arr\u00e1ez","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2025.08.006_bib41","first-page":"307","article-title":"Cytokines--central factors in alcoholic liver disease","volume":"27","author":"Neuman","year":"2003","journal-title":"Alcohol Res Health"},{"issue":"15","key":"10.1016\/j.cld.2025.08.006_bib42","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","article-title":"Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases","volume":"336","author":"Barnes","year":"1997","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2025.08.006_bib43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0168-8278(00)80219-6","article-title":"Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids","volume":"32","author":"Ta\u00efeb","year":"2000","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.08.006_bib44","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/0016-5085(80)90867-7","article-title":"Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy","volume":"78","author":"Depew","year":"1980","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cld.2025.08.006_bib45","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/0003-4819-110-9-685","article-title":"Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial","volume":"110","author":"Carithers","year":"1989","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.cld.2025.08.006_bib46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/gut.37.1.113","article-title":"Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables","volume":"37","author":"Christensen","year":"1995","journal-title":"Gut"},{"issue":"17","key":"10.1016\/j.cld.2025.08.006_bib47","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib48","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or Placebo-a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2025.08.006_bib49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL Clinical Practice guidelines: management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2025.08.006_bib50","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000573","article-title":"Comparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis","volume":"8","author":"Islam","year":"2024","journal-title":"Hepatol Commun"},{"issue":"8","key":"10.1016\/j.cld.2025.08.006_bib51","first-page":"478","article-title":"Practical concerns and controversies in the management of alcoholic hepatitis","volume":"12","author":"Im","year":"2016","journal-title":"Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.08.006_bib52","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2021.06.019","article-title":"Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: a worldwide study","volume":"75","author":"Arab","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.08.006_bib53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/jhep.2000.8627","article-title":"Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial","volume":"32","author":"Cabr\u00e9","year":"2000","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2025.08.006_bib54","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.21607","article-title":"The lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids","volume":"45","author":"Louvet","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2025.08.006_bib55","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ajg.2017.76","article-title":"Corrigendum: a Day-4 lille model predicts response to corticosteroids and mortality in severe alcoholic hepatitis","volume":"112","author":"Garcia-Saenz-de-Sicilia","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib56","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/j.cgh.2021.01.042","article-title":"Trajectory of serum bilirubin predicts spontaneous recovery in a real-world cohort of patients with alcoholic hepatitis","volume":"20","author":"Parker","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.08.006_bib57","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/ajt.13586","article-title":"Early liver transplantation for severe alcoholic hepatitis in the United States--A single-center experience","volume":"16","author":"Im","year":"2016","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib58","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2009.04.062","article-title":"Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor","volume":"137","author":"Louvet","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2025.08.006_bib59","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1440-1746.2002.02722.x","article-title":"Treatment of alcoholic hepatitis","volume":"17","author":"Maher","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.08.006_bib60","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2014.11.003","article-title":"Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding","volume":"62","author":"Rudler","year":"2015","journal-title":"J Hepatol"},{"issue":"6198","key":"10.1016\/j.cld.2025.08.006_bib61","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1136\/bmj.2.6198.1097","article-title":"Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning","volume":"2","author":"Prescott","year":"1979","journal-title":"Br Med J"},{"issue":"33","key":"10.1016\/j.cld.2025.08.006_bib62","first-page":"786","article-title":"N-acetylcysteine in acute hepatic failure (non-paracetamol-induced)","volume":"47","author":"Ben-Ari","year":"2000","journal-title":"Hepatogastroenterology"},{"issue":"19","key":"10.1016\/j.cld.2025.08.006_bib63","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis","volume":"365","author":"Nguyen-Khac","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2025.08.006_bib64","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1053\/j.gastro.2015.06.006","article-title":"Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis","volume":"149","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2025.08.006_bib65","first-page":"331","article-title":"The effect of pentoxifylline on the deformability of erythrocytes and on the muscular oxygen pressure in patients with chronic arterial disease","volume":"10","author":"Ehrly","year":"1979","journal-title":"J Med"},{"issue":"6","key":"10.1016\/j.cld.2025.08.006_bib66","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","volume":"119","author":"Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2025.08.006_bib67","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jhep.2007.10.010","article-title":"Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids","volume":"48","author":"Louvet","year":"2008","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.08.006_bib68","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2013.276300","article-title":"Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial","volume":"310","author":"Mathurin","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cld.2025.08.006_bib69","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.32478","article-title":"IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis","volume":"76","author":"Szabo","year":"2022","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2025.08.006_bib70","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/hep.22317","article-title":"Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial","volume":"48","author":"Spahr","year":"2008","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2025.08.006_bib71","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/ajg.2014.154","article-title":"Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study","volume":"109","author":"Singh","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2025.08.006_bib72","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/hep.30516","article-title":"Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial","volume":"70","author":"Shasthry","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2025.08.006_bib73","article-title":"Granulocyte colony-stimulating factor for alcoholic hepatitis: a systematic review and meta-analysis of randomised controlled trials","volume":"2","author":"Marot","year":"2020","journal-title":"JHEP Rep"},{"issue":"9","key":"10.1016\/j.cld.2025.08.006_bib74","article-title":"Efficacy of granulocyte colony stimulating factor in severe alcoholic hepatitis: a systematic review and meta-analysis","volume":"12","author":"Baig","year":"2020","journal-title":"Cureus"},{"issue":"19","key":"10.1016\/j.cld.2025.08.006_bib75","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1105703","article-title":"Early liver transplantation for severe alcoholic hepatitis","volume":"365","author":"Mathurin","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2025.08.006_bib76","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/SLA.0000000000001831","article-title":"Three-year results of a pilot program in early liver transplantation for severe alcoholic hepatitis","volume":"265","author":"Lee","year":"2017","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.cld.2025.08.006_bib77","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.gastro.2018.04.009","article-title":"Outcomes of early liver transplantation for patients with severe alcoholic hepatitis","volume":"155","author":"Lee","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.08.006_bib78","article-title":"The survival benefit of reabstinence after harmful alcohol use following early liver transplant for severe alcohol-associated hepatitis: a multicenter ACCELERATE study","author":"Dukewich","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2025.08.006_bib79","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S2468-1253(21)00430-1","article-title":"Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study","volume":"7","author":"Louvet","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:03:50Z","timestamp":1763762630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125000790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1089326125000790"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.08.006","relation":{},"ISSN":["1089-3261"],"issn-type":[{"type":"print","value":"1089-3261"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Treatments and Outcomes in Acute Alcohol-Related Hepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}